
Characteristics of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation in patients with chronic active Epstein–Barr virus disease: favorable responses to rituximab
Without treatment, CAEBV patients develop progressive cellular and humoural immune


















